Bladder Cancer
Each year, more than 81,000 new cases of bladder cancer are diagnosed in the United States, overwhelmingly among men (by more than 3:1). Thankfully, this type of cancer isn’t aggressive, allowing ample time for treatment. To get this treatment, rely on the team at Charleston Oncology for the most up-to-date protocols. If you’re dealing with bladder cancer, call today to request an appointment.
Board Certified Oncologists Specializing in Bladder Cancer
Downtown, Mt. Pleasant, West Ashley
N. Charleston, Summerville, Walterboro
Bladder Cancer Q & A
What is the difference between non-muscle-invasive and muscle-invasive bladder cancer?
Bladder cancer is classified primarily by how deeply it has grown into the bladder wall. Non-muscle-invasive bladder cancer (NMIBC) is confined to the inner lining and is generally managed with endoscopic surgery and intravesical therapies delivered directly into the bladder. Muscle-invasive bladder cancer (MIBC) has grown into the muscular layer and typically requires more aggressive treatment, which may include radical cystectomy, chemotherapy, immunotherapy, or radiation. The distinction between these two stages significantly shapes the treatment plan your oncologist will recommend.
What role does Charleston Oncology play in my bladder cancer care?
Medical oncologists are a central part of the bladder cancer care team. Our role includes designing and overseeing systemic treatment — chemotherapy, immunotherapy, and targeted therapies — and coordinating closely with urologic oncologists who perform surgical procedures and with radiation oncologists when radiation is part of the plan. Your Charleston Oncology oncologist ensures all aspects of your care are integrated and aligned with the most current evidence-based guidelines.
What are the most common symptoms of bladder cancer I should know about?
The most common and often first symptom of bladder cancer is blood in the urine (hematuria) — which may make urine appear pink, orange, or red, or may only be detectable on a urine test. Other symptoms can include frequent or urgent urination, pain or burning during urination, and pelvic pain. Blood in the urine can come and go, and its intermittent nature does not mean the underlying cause is benign. Any episode of blood in the urine warrants prompt evaluation by a physician.
Is immunotherapy used for bladder cancer, and how effective is it?
Yes — immunotherapy has become an important part of bladder cancer treatment, particularly for advanced or metastatic disease. Immune checkpoint inhibitors are used in patients whose cancer has progressed after chemotherapy or in patients who are not eligible for platinum-based chemotherapy. Pembrolizumab has also shown benefit as maintenance therapy following chemotherapy. Your oncologist will assess your tumor’s biomarker profile to determine whether immunotherapy is appropriate.
What happens if my bladder cancer recurs after treatment?
Bladder cancer recurrence is not uncommon, particularly for non-muscle-invasive disease — which is why ongoing surveillance with cystoscopy is essential. When recurrence occurs, treatment options depend on the location, stage, and characteristics of the recurrent tumor, as well as prior treatments. Options may include additional endoscopic surgery, alternative intravesical therapies, systemic chemotherapy, immunotherapy, targeted therapy, or clinical trial participation. Your Charleston Oncology team will thoroughly reassess your case and develop an updated strategy.
